Cited by 171Attention Deficit Hyperactivity DisorderSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders

Wilens, Timothy E., Adler, Lenard A., Weiss, Margaret D., Michelson, David, Ramsey, Janet L., Moore, Rodney J., Renard, Didier, Brady, Kathleen T., Trzepacz, Paula T., Schuh, Leslie M., Ahrbecker, Lisa M., Levine, Louise R.·2008·Drug and Alcohol Dependence

DOI 10.1016/j.drugalcdep.2008.02.009

Open this paper in CoChat — free account

Abstract

Objective Adults with attention-deficit/hyperactivity disorder (ADHD) have higher rates of alcohol and drug use disorders than adults without ADHD. The study aim was to determine if atomoxetine was superior to placebo in improving ADHD and alcohol use in recently abstinent adults with ADHD and comorbid alcohol use disorder.Methods Adults with DSM-IV diagnoses of ADHD and alcohol abuse and/or dependence were abstinent from alcohol at least 4 days (maximum 30 days) before study randomization. Participants received atomoxetine (25-100mg daily) or placebo for 12 weeks. ADHD symptoms were assessed using ADHD Investigator Symptom Rating Scale (AISRS) total score. Time-to-relapse to heavy alcohol use was analyzed using a 2-sided log-rank test based on Kaplan-Meier estimates and cumulative heavy drinking events over time were evaluated post hoc with recurrent-event analysis.Results Subjects received atomoxetine (n=72) or placebo (n=75) and 80 subjects completed the 12-week double-blind period (n=32 and 48, respectively). ADHD symptoms were significantly improved in the atomoxetine cohort compared to placebo (AISRS total score mean [S.D.], atomoxetine: -13.63 [11.35], P<.001; placebo: -8.31 [11.44], P<.001, difference: P=.007; effect size=0.48). No significant differences between treatment groups occurred in time-to-relapse of heavy drinking (P=.93). However, cumulative heavy drinking days were reduced 26% in atomoxetine-treated subjects versus placebo (event ratio=0.74, P=.023). There were no serious adverse events or specific drug-drug reactions related to current alcohol use.Conclusions This 3-month, double-blind, placebo-controlled study of atomoxetine in adults with ADHD and comorbid alcohol use disorder demonstrates clinically significant ADHD improvement, and inconsistent effects on drinking behavior.

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2008.02.009

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
Hamilton, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Self-citation
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects
(2001) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2001.tb01222.x · Cited by 3,515
The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452
Self-citation
A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930

Show all 69 references

Sorted by citations

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“The non stimulant atomoxetine may be an alternative to treatment with stimulants in substance abuse patients with ADHD, although studies showing superiority over stimulants in this difficult patient population are still lacking [200,284-286].”
Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis
van Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., Smit, F., Crunelle, C. L., Swets, M., & Schoevers, R. A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.12.007 · Cited by 535
Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood
Wilens, T. E., & Spencer, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2206 · Cited by 324
Self-citation
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders
Zulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-013-0436-6 · Cited by 214
Self-citation
Noradrenergic modulation of cognition: Therapeutic implications
Chamberlain, S. R., & Robbins, T. W. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480988 · Cited by 211
International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder
Crunelle, C., van den Brink, W., Moggi, F., Konstenius, M., Franck, J., Levin, F., van de Glind, G., Demetrovics, Z., Coetzee, C., Luderer, M., et al. (2018) · European Addiction Research · doi:10.1159/000487767 · Cited by 150
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder
Adler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176
Self-citation
Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder: A 6-Month, Double-Blind Trial
Adler, L., Spencer, T., Brown, T. E., Holdnack, J., Saylor, K. E., Schuh, K., Trzepacz, P., Williams, D., & Kelsey, D. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e4a0 · Cited by 150
Self-citation
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders
Riggs, P. D., Winhusen, T., Davies, R. D., Leimberger, J. D., Mikulich-Gilbertson, S., Klein, C., Macdonald, M., Lohman, M., Bailey, G. L., Haynes, L., et al. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.06.010 · Cited by 124
Treatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults
Wilens, T. E., Morrison, N. R., & Prince, J. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.137 · Cited by 117
Self-citation
ADHD and Anxiety: Clinical Significance and Treatment Implications
Reimherr, F. W., Marchant, B. K., Gift, T. E., & Steans, T. A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0859-6 · Cited by 113
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Levin, F. R., Mariani, J. J., Pavlicova, M., Brooks, D., Glass, A., Mahony, A., Nunes, E. V., Bisaga, A., Dakwar, E., Carpenter, K. M., et al. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.025 · Cited by 109
Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines
Ramos‐Quiroga, J. A., Montoya, A., Kutzelnigg, A., Deberdt, W. G., & Sobanski, E. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.812961 · Cited by 113
Alcohol use disorders and ADHD.
Luderer, M., Ramos Quiroga, J. A., Faraone, S. V., Zhang-James, Y., & Reif, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.010 · Cited by 102
The Intersection of Attention-deficit/Hyperactivity Disorder and Substance Abuse
Wilens, T., & Morrison, N. R. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328345c956 · Cited by 111
Self-citation
Trait Impulsive Choice Predicts Resistance to Extinction and Propensity to Relapse to Cocaine Seeking: A Bidirectional Investigation
Broos, N., Diergaarde, L., Schoffelmeer, A. N. M., Pattij, T., & Vries, T. J. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.323 · Cited by 101
Randomized, Controlled Trial of Atomoxetine for Attention-Deficit/Hyperactivity Disorder in Adolescents With Substance Use Disorder
Thurstone, C., Riggs, P. D., Salomonsen-Sautel, S., & Mikulich-Gilbertson, S. K. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.02.013 · Cited by 96
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
Kosheleff, A. R., Mason, O., Jain, R., Koch, J., & Rubin, J. S. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231158572 · Cited by 116
A Placebo‐Controlled Trial of Atomoxetine in Marijuana‐Dependent Individuals with Attention Deficit Hyperactivity Disorder
McRae‐Clark, A. L., Carter, R. E., Killeen, T. K., Carpenter, M. J., White, K., & Brady, K. T. (2010) · American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00076.x · Cited by 90
Self-citation
The role of impulsivity in relapse vulnerability
Pattij, T., & Vries, T. J. D. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.01.023 · Cited by 97
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis
Elliott, J., Johnston, A., Husereau, D., Kelly, S., Eagles, C., Charach, A., Hsieh, S., Bai, Z., Hossain, A., Skidmore, B., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240584 · Cited by 103
Cognitive enhancers in the treatment of substance use disorders: Clinical evidence
Brady, K. T., Gray, K. M., & Tolliver, B. K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.017 · Cited by 84
Self-citation
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: A pilot study
Konstenius, M., Jayaram-Lindström, N., Beck, O., & Franck, J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.006 · Cited by 83
Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3473 · Cited by 70
Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544777 · Cited by 78
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
Upadhyaya, H. P., Desaiah, D., Schuh, K. J., Bymaster, F. P., Kallman, M. J., Clarke, D. O., Durell, T. M., Trzepacz, P. T., Calligaro, D. O., Nisenbaum, E. S., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2986-z · Cited by 68
Self-citation
Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?
Carpentier, P. J., & LEVIN, F. R. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000122 · Cited by 69
Selective Norepinephrine Reuptake Inhibition by Atomoxetine Prevents Cue-Induced Heroin and Cocaine Seeking
Economidou, D., Dalley, J. W., & Everitt, B. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.040 · Cited by 64
Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
A critical appraisal of atomoxetine in the management of ADHD
Childress, A. C. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s59270 · Cited by 65
Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine
Wilens, T. E., Adler, L. A., Tanaka, Y., Xiao, F., D’Souza, D. N., Gutkin, S. W., & Upadhyaya, H. P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.628648 · Cited by 61
Self-citation
Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD
Brown, T. E., Holdnack, J., Saylor, K., Adler, L., Spencer, T., Williams, D. W., Padival, A. K., Schuh, K., Trzepacz, P. T., & Kelsey, D. (2011) · Journal of Attention Disorders · doi:10.1177/1087054709356165 · Cited by 59
Self-citation
Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Subtype/Presentation: Research Progress and Translational Studies
Peña, I. D., Pan, M. C., Thai, C. G., & Alisso, T. (2020) · Brain Sciences · doi:10.3390/brainsci10050292 · Cited by 76
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
Clemow, D. B., Bushe, C., Mancini, M., Ossipov, M. H., & Upadhyaya, H. P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s115707 · Cited by 59
Substance-use disorders in adolescents and adults with ADHD: focus on treatment
Wilens, T., & Morrison, N. R. (2012) · Neuropsychiatry · doi:10.2217/npy.12.39 · Cited by 53
Self-citation
Meta-Analysis of Suicide-Related Behavior or Ideation in Child, Adolescent, and Adult Patients Treated with Atomoxetine
Bangs, M. E., Wietecha, L. A., Wang, S., Buchanan, A. S., & Kelsey, D. K. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0005 · Cited by 52
Pharmacotherapy of ADHD in Adults
Wilens, T. E. (2008) · CNS Spectrums · doi:10.1017/s1092852900002960 · Cited by 50
Self-citation
Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician
Barbuti, M., Maiello, M., Spera, V., Pallucchini, A., Brancati, G., Maremmani, A., Perugi, G., & Maremmani, I. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093096 · Cited by 47
“Atomoxetine was effective in reducing ADHD symptomatology, but it did not have an impact on the relapse into heavy drinking [69].”
Background
Prevalence Estimates of ADHD in a Sample of Inpatients With Alcohol Dependence
Luderer, M., Sick, C., Kaplan-Wickel, N., Reinhard, I., Richter, A., Kiefer, F., & Weber, T. (2018) · Journal of Attention Disorders · doi:10.1177/1087054717750272 · Cited by 53
Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial
Levin, F., Mariani, J., Secora, A., Brooks, D. J., Cheng, W., Bisaga, A., Nunes, E., Aharonovich, E., Raby, W. N., & Hennessy, G. (2009) · Journal of dual diagnosis · doi:10.1080/15504260802628767 · Cited by 47
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-Analysis
Radonjić, N. V., Bellato, A., Khoury, N. M., Cortese, S., & Faraone, S. V. (2023) · CNS Drugs · doi:10.1007/s40263-023-01005-8 · Cited by 45
Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines
Preuss, U. W., Gouzoulis‐Mayfrank, E., Havemann‐Reinecke, U., Schäfer, I., Beutel, M. E., Hoch, E., & Mann, K. F. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0801-2 · Cited by 43
Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review
Hutchison, S. L., GHUMAN, J. K., Ghuman, H. S., Karpov, I. O., & Schuster, J. M. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316647686 · Cited by 42
Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial
Oortmerssen, K. V. E.-V., Vedel, E., Koeter, M., de Bruijn, K., Dekker, J., van den Brink, W., & Schoevers, R. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-132 · Cited by 41
Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD)
Perugi, G., Pallucchini, A., Rizzato, S., Rossi, P. D., Sani, G., Maremmani, A. G. I., Pinzone, V., & Maremmani, I. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551878 · Cited by 38
Reduced striatal brain volumes in non-medicated adult ADHD patients with comorbid cocaine dependence.
van Wingen, G. V., van den Brink, W., Veltman, D., Schmaal, L., Dom, G., Booij, J., & Crunelle, C. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.05.007 · Cited by 36
Pharmacological and clinical dilemmas of prescribing in co‐morbid adult attention‐deficit/hyperactivity disorder and addiction
Cobos, J. P. D. L., Siñol, N., Pérez, V., & Trujols, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12045 · Cited by 38
The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder
Perugi, G., & Vannucchi, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1079620 · Cited by 38
Towards Precision Addiction Treatment: New Findings in Co-morbid Substance Use and Attention-Deficit Hyperactivity Disorders
Luo, S. X., & LEVIN, F. R. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0769-7 · Cited by 40
Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD)
Perugi, G., Pallucchini, A., Rizzato, S., Pinzone, V., & Rossi, P. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1618270 · Cited by 35
Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study
Upadhyaya, H., Ramos-Quiroga, J., Adler, L., Williams, D. R., Tanaka, Y., Lane, J. R., Escobar, R., Trzepacz, P., Camporeale, A., & Allen, A. (2013) · The European Journal of Psychiatry · doi:10.4321/s0213-61632013000300004 · Cited by 28
Self-citation
Pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) and retention in outpatient substance use disorder treatment: a retrospective cohort study.
Kast, K., Rao, V., & Wilens, T. (2021) · Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13598 · Cited by 18
Self-citation
Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials
Camporeale, A., Porsdal, V., Bruyckere, K. D., Tanaka, Y., Upadhyaya, H. P., Deix, C., & Deberdt, W. G. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114560183 · Cited by 29
Inhibition of G-Protein-Activated Inwardly Rectifying K+ Channels by the Selective Norepinephrine Reuptake Inhibitors Atomoxetine and Reboxetine
Kobayashi, T., Washiyama, K., & Ikeda, K. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.27 · Cited by 29
Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence.
Adler, L., Wilens, T., Zhang, S.-Y., Durell, T. M., Walker, D., Schuh, L., Jin, L., Feldman, P., & Trzepacz, P. (2009) · American Journal on Addictions · doi:10.3109/10550490903077663 · Cited by 27
Self-citation
Urinary side effects of psychotropic drugs: A systematic review and metanalysis
Trinchieri, M., Perletti, G., Magri, V., Stamatiou, K., Montanari, E., & Trinchieri, A. (2021) · Neurourology and Urodynamics · doi:10.1002/nau.24695 · Cited by 25
ADHD with comorbid substance use disorder: review of treatment
Magon, R., & Müller, U. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009340 · Cited by 29
Interventions with potential to target executive function deficits in addiction: current state of the literature
Lechner, W. V., Sidhu, N. K., Kittaneh, A. A., & Anand, A. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.01.017 · Cited by 38
Methylphenidate for Attention-Deficit and Hyperactivity Disorder in Adult Patients With Substance Use Disorders: Good Clinical Practice
Chamakalayil, S., Strasser, J., Vogel, M., Brand, S., Walter, M., & Dürsteler, K. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.540837 · Cited by 32
ADHS im Erwachsenenalter und substanzbezogene Störungen – Prävalenz, Diagnostik und integrierte Behandlungskonzepte
Schecke, H., Scherbaum, N., Kis, B., & Mette, C. (2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-100763 · Cited by 30
Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Szobot, C. M., & Bukstein, O. G. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.11.003 · Cited by 28
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients
Bushe, C., Day, K., Reed, V., Karlsdotter, K., Berggren, L., Pitcher, A., Televantou, F., & Haynes, V. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636105 · Cited by 31
ADHD and Substance Use Disorders in Young People
Taubin, D., Wilson, J. C., & Wilens, T. E. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.01.005 · Cited by 26
Self-citation
Open Label Pilot Study of Atomoxetine in Adults With ADHD and Substance Use Disorder
Adler, L. A., Guida, F. V., Irons, S., & Shaw, D. M. (2010) · Journal of Dual Diagnosis · doi:10.1080/15504263.2010.537224 · Cited by 24
Self-citation
Attention deficit hyperactivity disorder and substance misuse: an evaluation of causal hypotheses and treatment considerations
Young, S., & Sedgwick, O. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1059756 · Cited by 32
Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats
Söderpalm, B., Danielsson, K., de Bejczy, A., Adermark, L., & Ericson, M. (2019) · Addiction Biology · doi:10.1111/adb.12807 · Cited by 23
Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature
Barkla, X. M., McArdle, P., & Newbury‐Birch, D. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0657-9 · Cited by 29
Subchronic administration of atomoxetine causes an enduring reduction in context‐induced relapse to cocaine seeking without affecting impulsive decision making
Broos, N., Loonstra, R., van Mourik, Y., Schetters, D., Schoffelmeer, A. N. M., Pattij, T., & Vries, T. J. D. (2014) · Addiction Biology · doi:10.1111/adb.12168 · Cited by 21
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder
Walker, D. J., Mason, O., Clemow, D. B., & Day, K. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1081046 · Cited by 20
Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Bukstein, O. G. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_148 · Cited by 19
Adult Attention Deficit Hyperactivity Disorder in Patients with Substance Use Disorders: A Study from Southern India
Ganesh, S., Kandasamy, A., Sahayaraj, U. S., & Benegal, V. (2017) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.198945 · Cited by 19
Role of conduct problems in the relation between Attention-Deficit Hyperactivity disorder, substance use, and gaming.
Schoenmacker, G., Groenman, A., Sokolova, E., Oosterlaan, J., Rommelse, N., Roeyers, H., Oades, R., Faraone, S., Franke, B., Heskes, T., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.06.003 · Cited by 14
ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan
Mucci, F., Avella, M. T., & Marazziti, D. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190805153610 · Cited by 21
The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials
Ravishankar, V., Chowdappa, S. V., Benegal, V., & Muralidharan, K. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.017 · Cited by 19
Efficacy of Metadoxine Extended Release in Patients With Predominantly Inattentive Subtype Attention-Deficit/Hyperactivity Disorder
Manor, I., Newcorn, J. H., Faraone, S. V., Adler, L. A., & The Metadoxine Study Group (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2689 · Cited by 18
Self-citation
The efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptoms
Benegal, V., Viswanath, B., Narayanaswamy, J. C., Jose, S. P., Chakraborty, V., Sankar, D., Thennarasu, K., & Kesavan, M. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2013.07.007 · Cited by 16
Systematic Review and Meta‐Analysis: Treatment of Substance Use Disorder in Attention Deficit Hyperactivity Disorder
Fluyau, D., Revadigar, N., & Pierre, C. G. (2020) · American Journal on Addictions · doi:10.1111/ajad.13133 · Cited by 16
An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders.
Wilens, T. E., Prince, J. B., Waxmonsky, J. G., Doyle, R., Spencer, T., Martelon, M., & Evans, M. F. (2010) · PubMed · Cited by 16
Self-citation
Emerging Pharmacologic Treatments for Adolescent Substance Use: Challenges and New Directions
Miranda, R., & Padovano, H. T. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0098-7 · Cited by 16
Prevalence of Adult ADHD Co-morbidity in Alcohol Use Disorders in a General Hospital Setup
Lohit, S. R., Babu, G. N., Sharma, S., Rao, S., Shanmukhappa, S. B., & Matkar, A. V. (2019) · Indian Journal of Psychological Medicine · doi:10.4103/ijpsym.ijpsym_464_18 · Cited by 16
Review of Rationale for Neurofeedback Application in Adolescent Substance Abusers with Comorbid Disruptive Behavioral Disorders
Sokhadze, E. M., Stewart, C., Tasman, A., Daniels, R., & Trudeau, D. L. (2011) · Journal of Neurotherapy · doi:10.1080/10874208.2011.595298 · Cited by 16
Barriers to Implementation of Treatment Guidelines for ADHD in Adults With Substance Use Disorder
Matthys, F., Soyez, V., van den Brink, W., Joostens, P., Tremmery, S., & Sabbe, B. (2014) · Journal of Dual Diagnosis · doi:10.1080/15504263.2014.926691 · Cited by 16
The effects of compound stimulus extinction and inhibition of noradrenaline reuptake on the renewal of alcohol seeking
Furlong, T. M., Pan, M. J., & Corbit, L. H. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.130 · Cited by 17
Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder
Camporeale, A., Upadhyaya, H. P., Ramos‐Quiroga, J. A., Williams, D. W., Tanaka, Y., Lane, J. R., Escobar, R., Trzepacz, P. T., & Allen, A. J. (2013) · The European Journal of Psychiatry · doi:10.4321/s0213-61632013000300005 · Cited by 15
Self-citation
Lifetime evolution of ADHD treatment
Mucci, F., Carpita, B., Pagni, G., Vecchia, A. D., Bjedov, S., Pozza, A., & Marazziti, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02336-w · Cited by 15
Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine
Sobanski, E., Leppämäki, S., Bushe, C., Berggren, L., Casillas, M., & Deberdt, W. G. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.005 · Cited by 13
The Co-Occurrence of ADHD and Substance Use Disorders
Wilens, T. E., & Kaminski, T. A. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180613-01 · Cited by 14
Self-citation
Update on adult attention-deficit/hyperactivity disorder
Hammerness, P. G., Surman, C. B. H., & Miller, K. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0077-z · Cited by 12
Disentangling the Association between ADHD and Alcohol Use Disorder in Individuals Suffering from Bipolar Disorder: A Systematic Review and Meta-Analysis
Bartoli, F., Callovini, T., Calabrese, A., Cioni, R. M., Riboldi, I., Crocamo, C., & Carrà, G. (2021) · Brain Sciences · doi:10.3390/brainsci12010038 · Cited by 12
Addressing Dual Diagnosis Patients Suffering from Attention-Deficit Hyperactivity Disorders and Comorbid Substance Use Disorders
Martínez-Raga, J., Knecht, C., de Alvaro, R., Szerman, N., & Ruiz, P. (2012) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318277060c · Cited by 12
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder
Brancati, G. E., Magnesa, A., Acierno, D., Carli, M., Rosa, U. D., Froli, A., Gemignani, S., Ventura, L., Weiss, F., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370346 · Cited by 16
Pharmacotherapy of ADHD in adults
Prince, J. B., Morrison, N. R., & Wilens, T. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.023 · Cited by 11
Self-citation
Attention‐Deficit Hyperactivity Disorder: Clinical Considerations for Women
Marraccini, M. E., Weyandt, L. L., Guðmundsdóttir, B. G., Oster, D. R., & McCallum, A. (2017) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.12671 · Cited by 11
ADHS bei erwachsenen Patienten mit Substanzkonsumstörungen
Luderer, M., Kiefer, F., Reif, A., & Moggi, F. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0779-2 · Cited by 11
Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Coexisting Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments
Weiss, F., Tidona, S., Carli, M., Perugi, G., & Scarselli, M. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220830154002 · Cited by 11
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database
Bruyckere, K. D., Bushe, C., Bartel, C., Berggren, L., Kan, C. C., & Dittmann, R. (2016) · CNS Drugs · doi:10.1007/s40263-016-0346-3 · Cited by 11
Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.
Cunill, R., Castells, X., González-Pinto, A., Arrojo, M., Bernardo, M., Saiz, P., Flórez, G., Torrens, M., Tirado-Muñoz, J., Fonseca, F., et al. (2021) · Adicciones · doi:10.20882/adicciones.1569 · Cited by 13
Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice
Sifeddine, W., Ba-M’hamed, S., Landry, M., & Bennis, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00459-3 · Cited by 10

Authors: Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., Ahrbecker, L. M., & Levine, L. R.
Affiliations: Massachusetts General Hospital (US)
New York University (US)
University of British Columbia (CA)
Eli Lilly (United States) (US)
Medical University of South Carolina (US)
Corresponding author: Wilens, Timothy E.
ORCID: Wilens, Timothy E.
Adler, Lenard A.
Weiss, Margaret D.
Michelson, David
Moore, Rodney J.
Renard, Didier
Brady, Kathleen T.
Schuh, Leslie M.
Venue: Drug and Alcohol Dependence
Publisher: Elsevier BV
Published: 2008-07
Volume: 96
Issue: 1-2
Pages: 145-154
ISSN: 0376-8716 (ISSN-L)
DOI: 10.1016/j.drugalcdep.2008.02.009
OpenAlex: W2061126019
Cited by: 171
References: 69
Citations by year: 2026: 5 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 8 · 2017: 10 · 2016: 9 · 2015: 13 · 2014: 14 · 2013: 14 · 2012: 12
FWCI: 9.81
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug and Alcohol Dependence (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company (5U10DA015831-0, K24 DA016264)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: atomoxetine, adult ADHD, alcoholism, comorbidities, alcohol relapse, heavy drinking, ADHD symptoms, pharmacotherapy
MeSH terms: Atomoxetine Hydrochloride, Adult, Alcohol Drinking, Attention Deficit Disorder with Hyperactivity, Double-Blind Method, Female, Humans, Male, Placebos, Propylamines, Psychiatric Status Rating Scales, Comorbidity, Treatment Outcome, Adrenergic Uptake Inhibitors, Alcohol-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks